Deutsche Bank Sees Upside in Chelsea Therapeutics (CHTP) to $9 On FDA Approval

Deutsche Bank commented on Chelsea Therapeutics (NASDAQ: CHTP) following FDA panel backing of Northera and sees upside to $9/share.

The firm comments, "Most who voted No believe longer studies need to be conducted. All doctors believe a confirmatory trial is warranted. This, combined with an SPA & a very rare/sick patient population is a positive event for CHTP. Risk/reward into APPROVAL is 50% downside (~$1.50) and ~400% upside (~$9/share)."

The firm has a Buy rating and $9 target on CHTP.

For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.

Shares of Chelsea Therapeutics closed at $2.41 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• New Street Research Upgrades Micron Technology (MU) to Buy
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)